{"id":"bekanamycin","rwe":[],"tags":[{"label":"bekanamycin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01GB13","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"phase_3","safety":{"commonSideEffects":[]},"trials":["NCT01456780","NCT01953367","NCT05429671","NCT04867993","NCT06739382","NCT02873806","NCT02409290","NCT00000796","NCT07485010","NCT01740947","NCT02099240","NCT01337219","NCT07228702","NCT06404541","NCT02497365","NCT04310930"],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T15:44:05.192236","allNames":"kanamycin b","offLabel":[],"synonyms":["bekanamycin","Kanamycin B","aminodeoxykanamycin","kanendomycin","Nebramycin V"],"timeline":[],"aiSummary":"Kanamycin B, also known as Bekanamycin, is a small molecule antibiotic of the bekanamycin class. Its mechanism of action is not well-documented, but it is believed to target bacterial cell membranes. Bekanamycin is not FDA-approved for any indications, and its commercial status is unclear. Further research is needed to determine its efficacy and safety profile. As a result, it is not widely used in clinical practice.","brandName":"Kanamycin B","ecosystem":[],"mechanism":{"target":"3-oxoacyl-[acyl-carrier-protein] synthase 3","modality":"Small Molecule","drugClass":"bekanamycin","explanation":"Imagine the bacterial cell membrane as a protective shield. Bekanamycin inserts itself into this shield, causing it to become unstable and eventually leading to the cell's demise. This process ultimately results in the death of the bacterial cell, effectively treating the infection.","oneSentence":"Bekanamycin works by disrupting the bacterial cell membrane, ultimately leading to cell death.","technicalDetail":"Bekanamycin is believed to interact with the bacterial cell membrane, potentially disrupting its function and leading to cell lysis and death."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1520","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BEKANAMYCIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:55:10.000982","biosimilars":[],"competitors":[{"drugName":"tobramycin","drugSlug":"tobramycin","fdaApproval":"1975-06-11","patentExpiry":"Sep 12, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"gentamicin","drugSlug":"gentamicin","fdaApproval":"1970-06-19","genericCount":36,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"kanamycin","drugSlug":"kanamycin","fdaApproval":"1973-02-13","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"neomycin","drugSlug":"neomycin","fdaApproval":"1957-03-26","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"amikacin","drugSlug":"amikacin","fdaApproval":"1981-01-22","patentExpiry":"May 15, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"netilmicin","drugSlug":"netilmicin","fdaApproval":"1983-02-28","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"plazomicin","drugSlug":"plazomicin","fdaApproval":"2018-06-25","patentExpiry":"Nov 21, 2028","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"bekanamycin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"_fixedFields":["pubmed(24)"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"tobramycin","brandName":"tobramycin","genericName":"tobramycin","approvalYear":"1975","relationship":"same-class"},{"drugId":"gentamicin","brandName":"gentamicin","genericName":"gentamicin","approvalYear":"1970","relationship":"same-class"},{"drugId":"kanamycin","brandName":"kanamycin","genericName":"kanamycin","approvalYear":"1973","relationship":"same-class"},{"drugId":"neomycin","brandName":"neomycin","genericName":"neomycin","approvalYear":"1957","relationship":"same-class"},{"drugId":"amikacin","brandName":"amikacin","genericName":"amikacin","approvalYear":"1981","relationship":"same-class"},{"drugId":"netilmicin","brandName":"netilmicin","genericName":"netilmicin","approvalYear":"1983","relationship":"same-class"},{"drugId":"plazomicin","brandName":"plazomicin","genericName":"plazomicin","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01456780","phase":"Phase 4","title":"Relative Efficacy of Loteprednol (Lotemax®) vs. Loteprednol/Tobramycin (Zylet®) in Treatment of Chronic Ocular Surface Inflammation Associated With Meibomian Gland Dysfunction (MGD)/Posterior Blephari","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","isPivotal":false,"enrollment":60,"indication":"Meibomian Gland Dysfunction, Posterior Blepharitis","completionDate":"2017-06"},{"nctId":"NCT01953367","phase":"Phase 1","title":"Bioequivalence and Safety Study of Vantobra and TOBI Nebulizer Solutions in Healthy Subjects","status":"COMPLETED","sponsor":"Pari Pharma GmbH","isPivotal":false,"enrollment":72,"indication":"Cystic Fibrosis","completionDate":"2013-11"},{"nctId":"NCT05429671","phase":"Phase 3","title":"Drug Elution Profile and Minimum Inhibitory Concentration of Antibiotic-loaded Cement After Primary Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Rothman Institute Orthopaedics","isPivotal":true,"enrollment":50,"indication":"Total Knee Arthoplasty","completionDate":"2023-11-30"},{"nctId":"NCT04867993","phase":"NA","title":"Amikacin Pharmacokinetics to Optimize Dosing Recommendations and Patho(Physiological) Considerations in Neonates With Perinatal Asphyxia Treated With Hypothermia","status":"UNKNOWN","sponsor":"University of Sarajevo","isPivotal":false,"enrollment":80,"indication":"Asphyxia Neonatorum","completionDate":"2022-12"},{"nctId":"NCT06739382","phase":"Phase 3","title":"Management of Ventilation Acquired Pneumonia Caused by Pseudomonas and Acinetobacter Organisms in a Pediatric Center: a Randomized Controlled Study","status":"COMPLETED","sponsor":"Beni-Suef University","isPivotal":true,"enrollment":64,"indication":"Ventilation Acquired Pneumonia","completionDate":"2022-01-01"},{"nctId":"NCT02873806","phase":"Phase 4","title":"A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications (One a Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject) and a Postoperativ","status":"COMPLETED","sponsor":"Glaukos Corporation","isPivotal":false,"enrollment":53,"indication":"Open-angle Glaucoma","completionDate":"2019-11-08"},{"nctId":"NCT02409290","phase":"Phase 3","title":"STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB","status":"COMPLETED","sponsor":"IUATLD, Inc","isPivotal":true,"enrollment":588,"indication":"MDR-TB","completionDate":"2023-05-02"},{"nctId":"NCT00000796","phase":"NA","title":"A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment o","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":525,"indication":"HIV Infections, Tuberculosis","completionDate":"1998-10"},{"nctId":"NCT07485010","phase":"Phase 2","title":"A Multi-centre, Randomised Trial Comparing a Novel Combination Treatment (Arm D - Intravenous Sulbactam-durlobactam in Combination With Intravenous Ceftriaxone, Oral Amoxicillin, Oral Azithromycin and","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","isPivotal":false,"enrollment":300,"indication":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection","completionDate":"2031-07"},{"nctId":"NCT01740947","phase":"Phase 4","title":"Perioperative Selective Decontamination of the Digestive Tract (SDD) in Elective Colorectal Cancer Patients: a Multicenter Randomized Clinical Trial","status":"TERMINATED","sponsor":"H. Jaap Bonjer, PhD","isPivotal":false,"enrollment":485,"indication":"Colorectal Cancer","completionDate":"2017-03"},{"nctId":"NCT02099240","phase":"EARLY/Phase 1","title":"Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics","status":"TERMINATED","sponsor":"Julio Ramirez","isPivotal":false,"enrollment":11,"indication":"Osteomyelitis","completionDate":"2018-11-07"},{"nctId":"NCT01337219","phase":"Phase 1","title":"Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaide® in Patients With Cystic Fibrosis.","status":"UNKNOWN","sponsor":"Erempharma","isPivotal":false,"enrollment":36,"indication":"Cystic Fibrosis","completionDate":""},{"nctId":"NCT07228702","phase":"Phase 1","title":"Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection: An Open Label Individual Patient Study","status":"ENROLLING_BY_INVITATION","sponsor":"Vancouver Coastal Health","isPivotal":false,"enrollment":1,"indication":"Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection","completionDate":"2027-10"},{"nctId":"NCT06404541","phase":"Phase 4","title":"A Comparison Between the Ocular Surface of Different Concentrations of Benzalkonium Chloride Preservative in Postoperative Topical Medications After Cataract Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kasr El Aini Hospital","isPivotal":false,"enrollment":60,"indication":"Ocular Surface Disease, Dry Eye Syndromes","completionDate":"2024-05"},{"nctId":"NCT02497365","phase":"NA","title":"Besifloxacin Ophthalmic Suspension in Patients With Bacterial Keratitis: A Prospective, Randomized Clinical Study","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","isPivotal":false,"enrollment":32,"indication":"Bacterial Keratitis","completionDate":"2019-07"},{"nctId":"NCT04310930","phase":"Phase 2","title":"Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT)","status":"RECRUITING","sponsor":"The University of Queensland","isPivotal":true,"enrollment":300,"indication":"Pulmonary Disease Due to Mycobacteria (Diagnosis)","completionDate":"2030-06-30"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"15JT14C3GI","CHEBI":"CHEBI:28098","INN_ID":"2838","UMLSCUI":"C0053076","ChEMBL_ID":"CHEMBL176","KEGG_DRUG":"D07497","DRUGBANK_ID":"DB13673","PDB_CHEM_ID":" 9CS","PUBCHEM_CID":"439318","IUPHAR_LIGAND_ID":"12182","MESH_SUPPLEMENTAL_RECORD_UI":"C001495"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":24,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J01GB13","allCodes":["J01GB13"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}